AI-augmented SBCE can improve efficiency, consistency, and monitoring of CeD; however, adoption should remain human-in-the-loop and be anchored to safety protocols, including patency testing when retention risk is relevant. Equity considerations include serology-negative presentations in some populations and the need for calibrated thresholds aligned with real-world prevalence and costs.
Dhali et al. (Thu,) studied this question.